S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.48 (-0.26%)
AAPL   149.24 (+0.32%)
MSFT   307.58 (-0.21%)
FB   340.60 (+0.18%)
GOOGL   2,831.05 (-1.18%)
TSLA   863.99 (-0.03%)
AMZN   3,414.00 (-0.88%)
NVDA   221.03 (-0.84%)
BABA   177.37 (+0.21%)
NIO   39.56 (-1.17%)
CGC   14.15 (-1.32%)
GE   105.95 (+1.16%)
AMD   116.44 (+0.09%)
MU   68.28 (+1.05%)
T   25.89 (+1.17%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.28 (-0.53%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.88 (+0.20%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.48 (-0.26%)
AAPL   149.24 (+0.32%)
MSFT   307.58 (-0.21%)
FB   340.60 (+0.18%)
GOOGL   2,831.05 (-1.18%)
TSLA   863.99 (-0.03%)
AMZN   3,414.00 (-0.88%)
NVDA   221.03 (-0.84%)
BABA   177.37 (+0.21%)
NIO   39.56 (-1.17%)
CGC   14.15 (-1.32%)
GE   105.95 (+1.16%)
AMD   116.44 (+0.09%)
MU   68.28 (+1.05%)
T   25.89 (+1.17%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.28 (-0.53%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.88 (+0.20%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.48 (-0.26%)
AAPL   149.24 (+0.32%)
MSFT   307.58 (-0.21%)
FB   340.60 (+0.18%)
GOOGL   2,831.05 (-1.18%)
TSLA   863.99 (-0.03%)
AMZN   3,414.00 (-0.88%)
NVDA   221.03 (-0.84%)
BABA   177.37 (+0.21%)
NIO   39.56 (-1.17%)
CGC   14.15 (-1.32%)
GE   105.95 (+1.16%)
AMD   116.44 (+0.09%)
MU   68.28 (+1.05%)
T   25.89 (+1.17%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.28 (-0.53%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.88 (+0.20%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.48 (-0.26%)
AAPL   149.24 (+0.32%)
MSFT   307.58 (-0.21%)
FB   340.60 (+0.18%)
GOOGL   2,831.05 (-1.18%)
TSLA   863.99 (-0.03%)
AMZN   3,414.00 (-0.88%)
NVDA   221.03 (-0.84%)
BABA   177.37 (+0.21%)
NIO   39.56 (-1.17%)
CGC   14.15 (-1.32%)
GE   105.95 (+1.16%)
AMD   116.44 (+0.09%)
MU   68.28 (+1.05%)
T   25.89 (+1.17%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.28 (-0.53%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.88 (+0.20%)
NASDAQ:KNSA

Kiniksa Pharmaceuticals Stock Forecast, Price & News

$10.92
-0.05 (-0.46 %)
(As of 10/20/2021 03:59 PM ET)
Add
Compare
Today's Range
$10.79
$11.07
50-Day Range
$10.69
$13.11
52-Week Range
$10.62
$24.70
Volume11,551 shs
Average Volume448,270 shs
Market Capitalization$748.27 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.02
30 days | 90 days | 365 days | Advanced Chart
Receive KNSA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Kiniksa Pharmaceuticals logo

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KNSA
Employees
168
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.57 per share

Profitability

Net Income
$-161.38 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$748.27 million
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.18 out of 5 stars

Medical Sector

381st out of 1,360 stocks

Pharmaceutical Preparations Industry

175th out of 667 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions

Is Kiniksa Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kiniksa Pharmaceuticals stock.
View analyst ratings for Kiniksa Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Kiniksa Pharmaceuticals?

Wall Street analysts have given Kiniksa Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kiniksa Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Kiniksa Pharmaceuticals' next earnings date?

Kiniksa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Kiniksa Pharmaceuticals
.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) released its earnings results on Tuesday, August, 3rd. The company reported ($0.61) EPS for the quarter, topping the Zacks' consensus estimate of ($0.69) by $0.08. The firm earned $7.70 million during the quarter, compared to analyst estimates of $2.56 million.
View Kiniksa Pharmaceuticals' earnings history
.

How has Kiniksa Pharmaceuticals' stock been impacted by Coronavirus?

Kiniksa Pharmaceuticals' stock was trading at $16.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KNSA shares have decreased by 32.1% and is now trading at $10.93.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for KNSA?

2 analysts have issued 1-year price targets for Kiniksa Pharmaceuticals' stock. Their forecasts range from $24.00 to $24.00. On average, they expect Kiniksa Pharmaceuticals' share price to reach $24.00 in the next year. This suggests a possible upside of 119.6% from the stock's current price.
View analysts' price targets for Kiniksa Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Kiniksa Pharmaceuticals' key executives?

Kiniksa Pharmaceuticals' management team includes the following people:
  • Sanj K. Patel, Chairman & Chief Executive Officer
  • Mark Ragosa, Chief Financial Officer & Senior Vice President
  • John F. Paolini, Chief Medical Officer & Senior Vice President
  • Dana Martin, Senior VP-Global Medical Affairs
  • Ross Moat, Vice President & GM-Rilonacept Franchise

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals CEO Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among Kiniksa Pharmaceuticals' employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vigilare Wealth Management (0.03%). Company insiders that own Kiniksa Pharmaceuticals stock include John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends for Kiniksa Pharmaceuticals
.

Which major investors are buying Kiniksa Pharmaceuticals stock?

KNSA stock was bought by a variety of institutional investors in the last quarter, including Vigilare Wealth Management.
View insider buying and selling activity for Kiniksa Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $10.93.

How much money does Kiniksa Pharmaceuticals make?

Kiniksa Pharmaceuticals has a market capitalization of $748.96 million. The company earns $-161.38 million in net income (profit) each year or ($2.61) on an earnings per share basis.

How many employees does Kiniksa Pharmaceuticals have?

Kiniksa Pharmaceuticals employs 168 workers across the globe.

What is Kiniksa Pharmaceuticals' official website?

The official website for Kiniksa Pharmaceuticals is www.kiniksa.com.

Where are Kiniksa Pharmaceuticals' headquarters?

Kiniksa Pharmaceuticals is headquartered at CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 448081896257 or via email at [email protected].


This page was last updated on 10/20/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.